Literature DB >> 6740678

Pyrvinium pamoate lacks in vivo genotoxicity in the colon.

M T Goldberg.   

Abstract

Pyrvinium pamoate, a widely used anthelmintic drug, has been previously tested for genotoxicity with equivocal results. Assays with bacterial or yeast test strains yielded positive results while in vitro tests with mammalian cells yielded negative results. In this study, the genotoxicity of pyrvinium was studied in vivo in the mouse colon, the therapeutic site of action of this agent. 1,2-Dimethylhydrazine (DMH), a colon carcinogen, was tested simultaneously as a positive control. The colonic nuclear aberration assay was used to determine genotoxicity. Pyrvinium delivered orally in three vehicles was not genotoxic in the murine colon, even at doses up to 12.5 times the recommended human dosage.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6740678     DOI: 10.1016/0041-008x(84)90154-6

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  3 in total

1.  Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells.

Authors:  Fang Xu; Yingjie Zhu; Yuhong Lu; Zhi Yu; Jun Zhong; Yangqiu Li; Jingxuan Pan
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

2.  Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.

Authors:  Autumn S Downey; Curtis R Chong; Thaddeus K Graczyk; David J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

3.  Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis.

Authors:  Bin Li; Colin A Flaveny; Camilla Giambelli; Dennis Liang Fei; Lu Han; Brian I Hang; Feng Bai; Xin-Hai Pei; Vania Nose; Oname Burlingame; Anthony J Capobianco; Darren Orton; Ethan Lee; David J Robbins
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.